Novel |
TNFRSF1A |
TNF receptor superfamily member 1A |
- TNFR1-induced proapoptotic signaling
- Regulation of TNFR1 signaling
- TNFR1-induced NF-kappa-B signaling pathway
- TNFR1-mediated ceramide production
- TNFs bind their physiological receptors
- Interleukin-10 signaling
- TNF signaling
|
- 6-[3-(4-Morpholinyl)Propyl]-2-(3-Nitrophenyl)-5-Thioxo-5,6,-Dihydro-7h-Thienol[2',3':4,5]Pyrrolo[1,2-C]Imidazol-7-One
- Tasonermin
|
- Tumor necrosis factor receptor-associated periodic syndrome (TRAPS); Familial periodic fever
|
Novel |
TNK2 |
tyrosine kinase non receptor 2 |
|
- ATP
- Debromohymenialdisine
- Entrectinib
- Fostamatinib
|
|
Novel |
TP53 |
tumor protein p53 |
- Activation of NOXA and translocation to mitochondria
- Activation of PUMA and translocation to mitochondria
- Pre-NOTCH Transcription and Translation
- Oxidative Stress Induced Senescence
- Formation of Senescence-Associated Heterochromatin Foci (SAHF)
- Oncogene Induced Senescence
- DNA Damage/Telomere Stress Induced Senescence
- SUMOylation of transcription factors
- Autodegradation of the E3 ubiquitin ligase COP1
- Association of TriC/CCT with target proteins during biosynthesis
- Pyroptosis
- TP53 Regulates Metabolic Genes
- Ub-specific processing proteases
- Ovarian tumor domain proteases
- Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
- Interleukin-4 and Interleukin-13 signaling
- TP53 Regulates Transcription of DNA Repair Genes
- TP53 Regulates Transcription of Genes Involved in Cytochrome C Release
- TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain
- TP53 Regulates Transcription of Caspase Activators and Caspases
- TP53 Regulates Transcription of Death Receptors and Ligands
- TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
- TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain
- TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest
- Regulation of TP53 Expression
- Regulation of TP53 Activity through Phosphorylation
- Regulation of TP53 Degradation
- Regulation of TP53 Activity through Acetylation
- Regulation of TP53 Activity through Association with Co-factors
- Regulation of TP53 Activity through Methylation
- PI5P Regulates TP53 Acetylation
- G2/M DNA damage checkpoint
- G2/M Checkpoints
- Stabilization of p53
- Transcriptional activation of cell cycle inhibitor p21
- The role of GTSE1 in G2/M progression after G2 checkpoint
- Transcriptional Regulation by VENTX
- RUNX3 regulates CDKN1A transcription
- Regulation of PTEN gene transcription
- Regulation of PTEN gene transcription
- Loss of function of TP53 in cancer due to loss of tetramerization ability
- Signaling by ALK fusions and activated point mutants
- Regulation of NF-kappa B signaling
- Zygotic genome activation (ZGA)
- Factors involved in megakaryocyte development and platelet production
- PKR-mediated signaling
|
- Acetylsalicylic acid
- Zinc
- Triethyl phosphate
- AZD 3355
- 1-(9-ethyl-9H-carbazol-3-yl)-N-methylmethanamine
- Zinc acetate
- Zinc chloride
- Zinc sulfate, unspecified form
|
- Chronic myeloid leukemia (CML)
- Breast cancer
- Non-small cell lung cancer
- Gastric cancer
- Adult T-cell leukemia
- Choriocarcinoma
- Esophageal cancer
- Glioma
- Pancreatic cancer
- Vulvar cancer
- Multiple myeloma
- Choroid plexus papilloma
- Ovarian cancer
- Hepatocellular carcinoma
- Squamous cell carcinoma
- Endometrial Cancer
- Penile cancer
- Cancer of the anal canal
- Hairy-cell leukemia
- Oral cancer
- Adrenal carcinoma
- Malignant melanoma
- Burkitt lymphoma
- Thyroid cancer
- Basal cell carcinoma
- Small cell lung cancer
- Gallbladder cancer
- Bladder cancer
- Laryngeal cancer
- Kaposi's sarcoma
- Cholangiocarcinoma
- Chronic lymphocytic leukemia (CLL)
- Li-Fraumeni syndrome, including: Classic Li-Fraumeni syndrome (LFS); LFS-like syndrome (LFSL)
- Malignant pleural mesothelioma
- Osteosarcoma
- Colorectal cancer
|
Novel |
TRAF1 |
TNF receptor associated factor 1 |
- Regulation of TNFR1 signaling
- TNFR1-induced NF-kappa-B signaling pathway
|
|
|
Novel |
TRAF3 |
TNF receptor associated factor 3 |
- TRAF3 deficiency - HSE
- TNFR2 non-canonical NF-kB pathway
- TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway
- Ovarian tumor domain proteases
- TICAM1-dependent activation of IRF3/IRF7
- TRAF3-dependent IRF activation pathway
- Negative regulators of DDX58/IFIH1 signaling
- Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE)
- SARS-CoV-1 activates/modulates innate immune responses
- SARS-CoV-2 activates/modulates innate and adaptive immune responses
- Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7
- Regulation of TBK1, IKKε-mediated activation of IRF3, IRF7 upon TLR3 ligation
|
|
|
Novel |
TRAF6 |
TNF receptor associated factor 6 |
- PIP3 activates AKT signaling
- MyD88:MAL(TIRAP) cascade initiated on plasma membrane
- NOD1/2 Signaling Pathway
- TICAM1, RIP1-mediated IKK complex recruitment
- Regulated proteolysis of p75NTR
- Downstream TCR signaling
- NRIF signals cell death from the nucleus
- NRIF signals cell death from the nucleus
- p75NTR recruits signalling complexes
- NF-kB is activated and signals survival
- FCERI mediated NF-kB activation
- TAK1-dependent IKK and NF-kappa-B activation
- activated TAK1 mediates p38 MAPK activation
- JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
- CLEC7A (Dectin-1) signaling
- Ub-specific processing proteases
- Ovarian tumor domain proteases
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- TICAM1,TRAF6-dependent induction of TAK1 complex
- Interleukin-1 signaling
- TRAF6 mediated IRF7 activation
- TRAF6 mediated NF-kB activation
- TRAF6 mediated NF-kB activation
- IRAK1 recruits IKK complex
- IKK complex recruitment mediated by RIP1
- IRAK2 mediated activation of TAK1 complex
- TRAF6-mediated induction of TAK1 complex within TLR4 complex
- Alpha-protein kinase 1 signaling pathway
- SARS-CoV-1 activates/modulates innate immune responses
- SARS-CoV-2 activates/modulates innate and adaptive immune responses
- TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling
- TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
- IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation
- MyD88 dependent cascade initiated on endosome
- IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation
- Regulation of NF-kappa B signaling
- MyD88 cascade initiated on plasma membrane
|
|
|
Novel |
TRAT1 |
T cell receptor associated transmembrane adaptor 1 |
- PIP3 activates AKT signaling
- Downstream TCR signaling
- Constitutive Signaling by Aberrant PI3K in Cancer
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
|
|
|
Novel |
TRIM50 |
tripartite motif containing 50 |
- Antigen processing: Ubiquitination & Proteasome degradation
|
|
|
Novel |
TRIM7 |
tripartite motif containing 7 |
|
|
|
Novel |
TRIP10 |
thyroid hormone receptor interactor 10 |
- Clathrin-mediated endocytosis
- RHOQ GTPase cycle
|
|
|
Novel |
TRIP6 |
thyroid hormone receptor interactor 6 |
|
|
|
Novel |
TRPC6 |
transient receptor potential cation channel subfamily C member 6 |
- Effects of PIP2 hydrolysis
- Elevation of cytosolic Ca2+ levels
- TRP channels
- Role of second messengers in netrin-1 signaling
|
|
- Nephrotic syndrome and focal segmental glomerulosclerosis
|
Novel |
TRPV4 |
transient receptor potential cation channel subfamily V member 4 |
- TRP channels
- High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells
- High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells
|
- Cannabidiol
- Butamben
- Medical Cannabis
- Nabiximols
|
- Spinal muscular atrophy (SMA), including: SMA type I (SMA1) / Werdning-Hoffman disease; SMA type II (SMA2); SMA type III (SMA3) / Kugeleberg-Welander disease; SMA type IV (SMA4); X-linked SMA 2 (SMAX2); X-linked distal SMA 3 (DSMAX); Distal SMA autosomal recessive type 4 (DSMA4); Congenital distal spinal muscular atrophy (SMAL); SMA proximal adult autosomal dominant (SMAPAD)
- TRPV4-related skeletal dysplasias, including: Autosomal dominant brachyolmia; Spondylometaphyseal dysplasia, Kozlowski type (SMDK); Metatropic dysplasia; Spondyloepiphyseal dysplasia, Maroteaux type ; Parastremmatic dysplasia
- Distal hereditary motor neuropathies (dHMN)
- TRPV4-related peripheral neuropathies, including: Congenital distal spinal muscular atrophy (CDSMA); Scapuloperoneal spinal muscle atrophy (SPSMA); Hereditary motor and sensory neuropathy type IIC (HMSN IIC)
|
Novel |
TUB |
TUB bipartite transcription factor |
|
- (1R,2R,3S,4R,6S)-3,4,6-Trihydroxy-5-{[(S)-hydroxy(3-hydroxy-2-oxopropoxy)phosphoryl]oxy}-1,2-cyclohexanediyl bis[dihydrogen (phosphate)]
|
|
Novel |
TXK |
TXK tyrosine kinase |
- FCERI mediated Ca+2 mobilization
- FCERI mediated Ca+2 mobilization
|
- Fostamatinib
- Zanubrutinib
|
|
Novel |
TYRO3 |
TYRO3 protein tyrosine kinase |
|
|
|
Novel |
USP8 |
ubiquitin specific peptidase 8 |
- Downregulation of ERBB2:ERBB3 signaling
- Regulation of FZD by ubiquitination
- Ub-specific processing proteases
- Negative regulation of MET activity
|
|
|
Novel |
VCL |
vinculin |
- Platelet degranulation
- Smooth Muscle Contraction
- MAP2K and MAPK activation
- Neutrophil degranulation
- Signaling by moderate kinase activity BRAF mutants
- Signaling by high-kinase activity BRAF mutants
- Signaling by BRAF and RAF1 fusions
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- Signaling downstream of RAS mutants
- Signaling by RAF1 mutants
- Signaling by ALK fusions and activated point mutants
- Regulation of CDH1 Function
- High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells
- Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells
|
|
|
Novel |
VDR |
vitamin D receptor |
- Vitamin D (calciferol) metabolism
- Nuclear Receptor transcription pathway
- SUMOylation of intracellular receptors
|
- Calcitriol
- Calcifediol
- Ergocalciferol
- Cholecalciferol
- Paricalcitol
- Dihydrotachysterol
- Alfacalcidol
- Calcipotriol
- Lexacalcitol
- Seocalcitol
- Cholesterol
- Inecalcitol
- Becocalcidiol
- CTA018
- Eldecalcitol
- Elocalcitol
- Doxercalciferol
- (1R,3R)-5-[(2E)-3-{(1S,3R)-2,2,3-trimethyl-3-[6,6,6-trifluoro-5-hydroxy-5-(trifluoromethyl)hex-3-yn-1-yl]cyclopentyl}prop-2-en-1-ylidene]cyclohexane-1,3-diol
- 1,3-CYCLOHEXANEDIOL, 4-METHYLENE-5-[(2E)-[(1S,3AS,7AS)-OCTAHYDRO-1-(5-HYDROXY-5-METHYL-1,3-HEXADIYNYL)-7A-METHYL-4H-INDEN-4-YLIDENE]ETHYLIDENE]-, (1R,3S,5Z)
- Vitamin D
- Curcumin
- Curcumin sulfate
|
- Tuberculosis
- Localized autosomal recessive hypotrichosis
|
Novel |
VIL1 |
villin 1 |
|
|
|